Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines

Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines

High grade serous ovarian cancer (HGSOC) is the most common and aggressive ovarian cancer subtype with the worst clinical outcome due to intrinsic or acquired drug resistance. Standard treatment involves platinum compounds. Cancer development and chemoresistance is often associated with an increase...

Full description

Bibliographic Details
Main Authors: Jan J. Bandolik, Alexandra Hamacher, Christian Schrenk, Robin Weishaupt, Matthias U. Kassack
Format: Article
Language:English
Published: MDPI AG 2019-06-01
Series:International Journal of Molecular Sciences
Subjects:
cisplatin
high grade serous ovarian cancer (HGSOC)
histone deacetylase inhibitors
caspase activity
antitumor platinum agents
combination treatment
panobinostat
entinostat
nexturastat A
Online Access:https://www.mdpi.com/1422-0067/20/12/3052

Internet

https://www.mdpi.com/1422-0067/20/12/3052

Similar Items